4,034 Shares in Amgen Inc. (NASDAQ:AMGN) Bought by Jump Financial LLC

Jump Financial LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 4,034 shares of the medical research company's stock, valued at approximately $1,051,000.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Blossom Wealth Management boosted its position in shares of Amgen by 3.5% during the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after purchasing an additional 37 shares in the last quarter. Zullo Investment Group Inc. increased its holdings in Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock valued at $356,000 after buying an additional 37 shares in the last quarter. Trillium Asset Management LLC lifted its position in shares of Amgen by 4.2% during the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock valued at $237,000 after acquiring an additional 37 shares during the period. Evermay Wealth Management LLC grew its holdings in shares of Amgen by 1.5% in the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock worth $691,000 after acquiring an additional 38 shares during the period. Finally, Great Lakes Retirement Inc. increased its stake in Amgen by 0.4% in the 4th quarter. Great Lakes Retirement Inc. now owns 10,220 shares of the medical research company's stock valued at $2,664,000 after purchasing an additional 38 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 0.4 %

NASDAQ:AMGN traded up $1.00 on Friday, hitting $280.84. 1,994,531 shares of the stock were exchanged, compared to its average volume of 2,790,190. The stock has a fifty day moving average of $301.52 and a 200-day moving average of $292.83. The stock has a market cap of $150.99 billion, a PE ratio of 37.20, a PEG ratio of 2.63 and a beta of 0.59. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.39%. Amgen's dividend payout ratio is currently 126.09%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. Morgan Stanley upped their target price on Amgen from $328.00 to $330.00 and gave the company an "equal weight" rating in a report on Wednesday, April 9th. Cantor Fitzgerald started coverage on shares of Amgen in a report on Tuesday. They set a "neutral" rating and a $305.00 target price for the company. Johnson Rice set a $294.00 price target on shares of Amgen in a report on Wednesday, March 5th. Piper Sandler raised their price objective on shares of Amgen from $310.00 to $329.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen has an average rating of "Hold" and an average target price of $310.57.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the sale, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock valued at $20,644,335 in the last ninety days. Insiders own 0.69% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.